Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 11th 2014

Validating Electronic Cancer Quality Measures at Veterans Health Administration

Jeremy B. Shelton, MD, MSHS Ted A. Skolarus, MD, MPH Diana Ordin, MD, MPH Jennifer Malin, MD, PhD AnnaLiza Antonio, MS Joan Ryoo, MD, MSHS Christopher S. Saigal, MD

Even in a fully integrated healthcare system, only 28% of cancer quality measures could be validated by using electronically available data.

December 11th 2014

Slow Adoption of Less Costly, Patient-Preferred Radiation Therapy

Laura Joszt, MA

A majority of breast cancer patients in the US are receiving longer radiation therapy than is necessary and compared with their counterparts in other countries, according to a new study published in JAMA.

December 9th 2014

SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML

Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.

December 9th 2014

EPIC Trial Shows Ponatinib Effective in CML

On Monday, the third day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9, in San Francisco, Jeffrey H. Lipton, MD, PhD, chief, presented results from the EPIC trial, evaluating ponatinib in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

CML Updates: Defining MMR and Results of the DASISION Trial

December 9th 2014

CML Updates: Defining MMR and Results of the DASISION Trial

On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.

December 8th 2014

Giora Sharf Discusses Ways to Represent the CML Patient Voice

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

December 8th 2014

Dr Susanne Saussele Defines When Patients With CML Should Change Therapy

Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.

December 8th 2014

Evaluating Safety, Efficacy, and Outcomes of TKIs in CML

A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.

December 8th 2014

Jan Geissler Explains Differing Perceptions for Living With CML

Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.

December 8th 2014

Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.

December 8th 2014

TKIs and Molecular Response in CML: the EURO-SKI Study

On the second day at the Annual Meeting of the American Society of Hematology 2014, Francois-Xavier Mahon, MD, PhD, Bordeaux Hospital, INSERM 1035, Bordeaux, France, shared the results from the European LeukemiaNet Stop TKI (EURO-SKI) study; the trial used tyrosine kinase inhibitors (TKIs) in CML to define prognostic markers to increase the rate of patients in durable deep molecular response after stopping TKI.

Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorefenib in AML

December 8th 2014

Best of ASH Presentations: Platelets, Lenalidomide for MDS, and Sorefenib in AML

The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.

December 7th 2014

Greg Stephens Offers Advice for the Newly Diagnosed CML Patient

One of the reoccurring themes at the 56th Annual Meeting of the American Society of Hematology was the importance of proper monitoring, said Greg Stephens, executive director of the National CML Society.

December 7th 2014

Dr Elaine Fuchs Explains How Stem Cell Discoveries Fuel Cancer Therapeutics

Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, said Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University.

Healthcare Costs in Need of Solutions: Experts at ASH Agree

December 7th 2014

Healthcare Costs in Need of Solutions: Experts at ASH Agree

While medical oncologists, drug developers, and research scientists presented their research findings and novel treatment options in hematological cancers, a special session in the afternoon on the first day of the 56th Annual Meeting of the American Society of Hematology (ASH), held December 6 to 9 in San Francisco, addressed the aspect of cost of care and the increasing financial burden faced by the cancer patient.

Dr Mark G. Kris on Use of the Patient's Genome

December 5th 2014

Dr Mark G. Kris on Use of the Patient's Genome

Recent important changes in oncology have led to major advances that allow providers to recommend very specific therapies, said Mark G. Kris, MD, William and Joy Ruane chair in thoracic oncology at Memorial Sloan Kettering Cancer Center.

December 5th 2014

Markers for Mental Health Problems in Cancer Patients Identified

December 5th 2014

Rapid Progress in Bench-to-Clinic Reported for Several Cancers

The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.

December 4th 2014

340B: A Double-Edged Sword

While ASCO is calling to update the 340B drug discount program, hospitals that serve economically diverse populations make a case for the program: "Because of 340B, we don't have to turn patients away when they can't pay."

December 4th 2014

ASH Adds to the "Choosing Wisely" List

The American Society of Hematology has added 5 more recommendations to it's Choosing Wisely list, which was published in the journal Blood,

December 4th 2014

Xalkori Shows Significant Benefit As First-Line in ALK-Positive NSCLC

The study, published in NEJM, found that PFS improved by nearly 4 months while ORR improved by nearly 30%.

December 4th 2014

Prostate Cancer Diagnostic Test Could Prevent Over or Under Treatment

By distinguishing low- and intermediate-risk patients, Oncotype DX is predicted to avoid over- and under-treatment of prostate cancer patients.

December 3rd 2014

Amgen's Blincyto Approved for B-Cell ALL

Blincyto, which was considered a promising immunotherapy with a novel mechanism of action, was approved 5 months prior to its PDUFA date.

December 3rd 2014

Gene Could Be a New Biomarker For Diagnosis of TNBC

Absence of a microRNA in TNBC resulted in the overexpression of RASAL2 in those tumors. Patients overexpressing RASAL2 had poorer survival, research showed.

December 3rd 2014

Most People Dismiss Early Signs of Cancer: PLOS ONE Study

People could be putting their lives at risk by dismissing potential warning signs of cancer as less serious symptoms, according to a Cancer Research UK-funded study published in PLOS ONE. The survey found that nearly 97% of people with symptoms failed to act on them.

December 2nd 2014

Bisphosphonates Can Prevent Certain Cancers: PNAS Study

A study found new indications for a drug that is widely used in the treatment of osteoarthritis, based on an observation that those on the medication had a lower incidence of several cancers.

December 2nd 2014

Astra Files NDA for Iressa as First-Line in NSCLC

Iressa, an EGFR inhibitor, is widely used in the treatment of advanced, metastatic NSCLC.

December 1st 2014

Cabozantinib Fails to Meet Primary End-Point in mCRPC

Failure of the drug in the phase 3 COMET-2 study was anticipated following the reported failure of the earlier COMET-1 trial.

November 30th 2014

AJMC Stakeholder Summit Explores Challenges in Using Data to Make Decisions in Oncology

What makes a cancer therapy effective may be in the eye of the stakeholder, even though everyone involved in healthcare decisions relies on evidence-based information. Evidence-Based Oncology, a publication of The American Journal of Managed Care, this month publishes a condensed version of the discussion among payers on how to improve collection and use of collection of data to make better evidence-based decisions in oncology.

November 30th 2014

Genes Could Predict

The NIH-funded study, published in the New England Journal of Medicine, identified mutations that are harbored early and could be potential early-onset biomarkers for detection.

...

145 146 147 148 149 150 151 152 153

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions